Birchview Capital »

Fibrogen shares owned by Birchview Capital

Quarter-by-quarter ownership of Fibrogen (KYNB) shares owned by Birchview Capital from 13F filings

Historical chart of Birchview Capital investment in Fibrogen

Tip: Access up to 7 years of quarterly data

All positions including Fibrogen held by Birchview Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Fibrogen by Birchview Capital

Quarter filed Position value Share count Share price at filing
2026-03-31 $153k 23k 6.78

More positions owned by Birchview Capital

Kla Corporation Com New (KLAC)
Bristol Myers Squibb (BMY)
Compass Therapeutics (CMPX)
Lam Research Corporation Com New (LRCX)
Stoke Therapeutics (STOK)
Encana Corporation (OVV)
Intellia Therapeutics (NTLA)
Structure Therapeutics Spons Adr (GPCR)
Solid Biosciences Com New (SLDB)
Prothena Corp SHS (PRTA)
Biodesix
ACADIA Pharmaceuticals (ACAD)
Protagonist Therapeutics (PTGX)
Neurocrine Biosciences (NBIX)
Olema Pharmaceuticals (OLMA)

View all positions for Birchview Capital

Top funds holding Fibrogen

Armistice Capital
Vanguard Capital Management
Acadian Asset Management
Susquehanna International
BlackRock
Two Sigma Investments
Geode Capital Management
HighTower Advisors
UBS Group
Renaissance Technologies
Vanguard Fiduciary Trust
Birchview Capital
State Street Corporation
Jane Street
ADAR1 Capital Management

View all funds holding Fibrogen